EA201891882A1 - НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ - Google Patents
НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯInfo
- Publication number
- EA201891882A1 EA201891882A1 EA201891882A EA201891882A EA201891882A1 EA 201891882 A1 EA201891882 A1 EA 201891882A1 EA 201891882 A EA201891882 A EA 201891882A EA 201891882 A EA201891882 A EA 201891882A EA 201891882 A1 EA201891882 A1 EA 201891882A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sirpa
- options
- new antibodies
- therapeutic application
- interaction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Настоящее изобретение относится к новым антителам к SIRPa, способным оказывать специфическое антагонистическое действие на взаимодействие SIRPa с CD47, не оказывая отрицательного влияния на взаимодействие SIRPg с CD47, а также к вариантам их применения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17305182 | 2017-02-17 | ||
PCT/EP2017/059071 WO2017178653A2 (en) | 2016-04-14 | 2017-04-14 | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201891882A1 true EA201891882A1 (ru) | 2019-07-31 |
Family
ID=58185461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201891882A EA201891882A1 (ru) | 2017-02-17 | 2017-04-14 | НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3443010A2 (ru) |
CN (1) | CN109071664B (ru) |
AU (1) | AU2017248626B2 (ru) |
BR (1) | BR112018070823A2 (ru) |
CA (1) | CA3020373A1 (ru) |
CO (1) | CO2018010855A2 (ru) |
EA (1) | EA201891882A1 (ru) |
PE (1) | PE20181921A1 (ru) |
SG (1) | SG11201808465UA (ru) |
WO (1) | WO2017178653A2 (ru) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY185014A (en) | 2015-08-07 | 2021-04-30 | Alx Oncology Inc | Contructs having a sirp-alpha domain or variant thereof |
JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
JP7173971B2 (ja) | 2016-12-09 | 2022-11-16 | アレクトル エルエルシー | 抗SIRP-α抗体及びその使用方法 |
EP3583128A1 (en) * | 2017-02-17 | 2019-12-25 | OSE Immunotherapeutics | New uses of anti-sirpg antibodies |
JP7160833B2 (ja) | 2017-04-13 | 2022-10-25 | サイロパ ビー.ブイ. | 抗sirpアルファ抗体 |
TWI710574B (zh) * | 2017-05-16 | 2020-11-21 | 荷蘭商拜恩迪斯公司 | 抗訊號調節蛋白α(SIRPα)抗體 |
CN111183155B (zh) | 2017-08-02 | 2024-02-20 | 凡恩世制药(北京)有限公司 | 抗cd47抗体及其用途 |
US11713356B2 (en) | 2017-10-13 | 2023-08-01 | Ose Immunotherapeutics | Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer |
EP3700938A1 (en) * | 2017-10-26 | 2020-09-02 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. | Novel recombinant fusion proteins, preparation and use thereof |
JP2021517130A (ja) | 2018-03-13 | 2021-07-15 | オーセ イミュノセラピューティクスOse Immunotherapeutics | 抗ヒトSIRPav1抗体の使用および抗v1抗体を製造する方法 |
WO2019178218A1 (en) * | 2018-03-14 | 2019-09-19 | Memorial Sloan Kettering Cancer Center | Anti-polysialic acid antibodies and uses thereof |
WO2019183266A1 (en) * | 2018-03-21 | 2019-09-26 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
CR20200566A (es) | 2018-05-25 | 2021-02-19 | Alector Llc | Anticuerpos anti-sirpa y metodos de utilización de los mismos |
TW202035449A (zh) * | 2018-07-10 | 2020-10-01 | 國立大學法人神戶大學 | 抗SIRPα抗體 |
US20230242640A1 (en) * | 2018-08-22 | 2023-08-03 | Ose Immunotherapeutics | ANTI-SIRPg Compounds |
MX2021003393A (es) * | 2018-09-27 | 2021-05-13 | Celgene Corp | Proteinas de fijacion a sirp alfa y metodos de uso de estas. |
US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
JP2022509480A (ja) | 2018-10-29 | 2022-01-20 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | 好中球のCD47-SIRPアルファチェックポイント阻害による異常な細胞のIgAによって媒介される致死 |
BR112021009325A2 (pt) * | 2018-11-14 | 2021-09-14 | Arch Oncology, Inc. | Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica |
JP7451520B2 (ja) | 2018-11-15 | 2024-03-18 | ビョンディス・ビー.ブイ. | ヒト化抗SIRPα抗体 |
US20220143210A1 (en) * | 2019-02-27 | 2022-05-12 | Fred Hutchinson Cancer Research Center | Hydrogel compositions and methods for treatement of malignancies |
EP3969476A1 (en) * | 2019-03-04 | 2022-03-23 | Qilu Puget Sound Biotherapeutics Corporation | Anti-sirp-alpha antibodies |
CA3141130A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
MA56119A (fr) | 2019-06-07 | 2022-04-13 | Alx Oncology Inc | Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques |
PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
EP3756688A1 (en) | 2019-06-25 | 2020-12-30 | Université de Nantes | Inhibitor of surface protein (sp-d) / sirpa / shp2 pathway for use in the prevention and/or treatment of secondary infection |
AU2020286285A1 (en) * | 2019-08-20 | 2021-03-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-SIRPa antibodies |
JP7371243B2 (ja) | 2019-10-18 | 2023-10-30 | フォーティ セブン, インコーポレイテッド | 骨髄異形成症候群及び急性骨髄性白血病を治療するための併用療法 |
CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
CA3162633A1 (en) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
CN111116713B (zh) * | 2020-01-07 | 2023-06-23 | 郑州大学 | Sirpa蛋白亲和环肽及其应用 |
CA3169451A1 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
TW202146056A (zh) | 2020-02-28 | 2021-12-16 | 美商泰勒克療法公司 | 轉穀胺醯胺酶介導之結合 |
CR20220586A (es) | 2020-05-19 | 2023-01-09 | Boehringer Ingelheim Int | Moléculas de fijación para el tratamiento de cáncer |
AU2021283083A1 (en) | 2020-06-01 | 2022-12-01 | ALX Oncology Inc. | Combination therapies comprising a hypomethylation agent for treating cancer |
CN116916919A (zh) | 2020-11-11 | 2023-10-20 | 第一三共株式会社 | 抗体-药物缀合物与抗SIRPα抗体的组合 |
EP4253416A1 (en) | 2020-11-30 | 2023-10-04 | Qure Biotechnology (Shanghai) Co., Ltd. | Anti-sirpalpha antibody or antigen-binding fragment thereof, and use thereof |
JP2023552375A (ja) | 2020-12-06 | 2023-12-15 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてcd47に結合する薬物の干渉を低減するための多量体 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
IL308400A (en) | 2021-05-13 | 2024-01-01 | Alx Oncology Inc | Combined therapies for cancer treatment |
TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用FLT3L—Fc融合蛋白之方法 |
CN117355539A (zh) * | 2021-05-28 | 2024-01-05 | 百奥泰生物制药股份有限公司 | 抗SIRPα抗体及其应用 |
AU2022284373A1 (en) | 2021-06-04 | 2024-01-04 | Boehringer Ingelheim International Gmbh | Anti-sirp-alpha antibodies |
US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
TW202317190A (zh) | 2021-06-29 | 2023-05-01 | 美商思進公司 | 以非岩藻糖基化抗cd70抗體及cd47拮抗劑之組合治療癌症之方法 |
CN116472351A (zh) | 2021-08-17 | 2023-07-21 | 杭州九源基因工程有限公司 | 靶向SIRPα的单克隆抗体及其用途 |
TW202330504A (zh) | 2021-10-28 | 2023-08-01 | 美商基利科學股份有限公司 | 嗒𠯤—3(2h)—酮衍生物 |
AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023094698A1 (en) | 2021-11-29 | 2023-06-01 | Ose Immunotherapeutics | Specific antagonist anti-sirpg antibodies |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2023235754A1 (en) | 2022-06-01 | 2023-12-07 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100215640A1 (en) * | 2003-04-24 | 2010-08-26 | The University Of North Carolina At Chapel Hill | Method for inhibiting cellular activation by insulin-like growth factor-1 |
US8613922B2 (en) * | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
US20090191202A1 (en) * | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
US20100239578A1 (en) * | 2007-10-11 | 2010-09-23 | University Health Network | Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
CN101780283A (zh) * | 2010-03-16 | 2010-07-21 | 中国人民解放军第二军医大学 | 信号调节蛋白α在制备预防和***的DC疫苗中的应用 |
CN101880324B (zh) * | 2010-05-25 | 2012-10-17 | 中国人民解放军第二军医大学 | 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用 |
AU2015229448B2 (en) * | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
-
2017
- 2017-04-14 CN CN201780023581.2A patent/CN109071664B/zh active Active
- 2017-04-14 PE PE2018001974A patent/PE20181921A1/es unknown
- 2017-04-14 AU AU2017248626A patent/AU2017248626B2/en active Active
- 2017-04-14 WO PCT/EP2017/059071 patent/WO2017178653A2/en active Application Filing
- 2017-04-14 EP EP17718881.0A patent/EP3443010A2/en active Pending
- 2017-04-14 CA CA3020373A patent/CA3020373A1/en active Pending
- 2017-04-14 SG SG11201808465UA patent/SG11201808465UA/en unknown
- 2017-04-14 BR BR112018070823A patent/BR112018070823A2/pt unknown
- 2017-04-14 EA EA201891882A patent/EA201891882A1/ru unknown
-
2018
- 2018-10-10 CO CONC2018/0010855A patent/CO2018010855A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2018010855A2 (es) | 2018-11-13 |
PE20181921A1 (es) | 2018-12-11 |
WO2017178653A2 (en) | 2017-10-19 |
BR112018070823A2 (pt) | 2019-02-05 |
CN109071664A (zh) | 2018-12-21 |
AU2017248626A1 (en) | 2018-10-11 |
WO2017178653A3 (en) | 2018-07-05 |
SG11201808465UA (en) | 2018-10-30 |
CN109071664B (zh) | 2023-02-21 |
CA3020373A1 (en) | 2017-10-19 |
EP3443010A2 (en) | 2019-02-20 |
AU2017248626B2 (en) | 2024-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201891882A1 (ru) | НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ | |
CL2019002824A1 (es) | Anticuerpos anti-lag3. | |
CL2019000424A1 (es) | Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos. | |
EA201890441A1 (ru) | Моноклональные антитела против bcma | |
CY1123259T1 (el) | Αντισωματα anti-pvrig και μεθοδοι χρησης | |
CO2019003943A2 (es) | Proteínas de fusión fc heterodiméricas il15/il15rα | |
SA517381604B1 (ar) | أجسام مضادة ديمرية غير متجانسة جديدة | |
EA201691991A1 (ru) | Мультиспецифические антитела | |
EA201791164A1 (ru) | Гетеродимерные антитела, связывающие cd3 и cd38 | |
EA201792414A1 (ru) | Антитела против cd166, активируемые антитела против cd166 и способы их применения | |
EA201790548A1 (ru) | Варианты комбинированной терапии анти-cd38 антителами | |
EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
EA201690314A1 (ru) | Анти-garp-белок и его применения | |
EA201691610A8 (ru) | Анти-jagged1 антитела и способы применения | |
PH12018550160A1 (en) | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS | |
EA201201016A1 (ru) | Антидоты антикоагулянтов | |
EA201600473A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ | |
CL2020002540A1 (es) | Anticuerpos anti-hla-g y utilización de los mismos | |
EA201892716A1 (ru) | Антитела к фактору свертывания xi | |
EA201891299A1 (ru) | Терапевтические антитела к cd9 | |
EA201890322A1 (ru) | Новый вид тобамовируса | |
EA202091521A1 (ru) | ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ | |
BR112018014355A2 (pt) | processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii | |
EA201691983A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов cb2 | |
EA201890347A1 (ru) | Антитела и исследования для обнаружения cd37 |